Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors
Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor Sponsor: Antoinette J Wozniak Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Gastroenterology | HNSCC | Melanoma | Non-Small Cell Lung Cancer | Research | Skin Cancer